We are studying yeast homologs of the synaptobrevin/ VAMP family of vesicle-associated membrane proteins, which act as vesicular compartment-soluble N-ethylmaleimide-sensitive factor attachment protein receptors (v-SNAREs) in cells having a capacity for stimuluscoupled secretion, as well as in other cell types. The yeast homologs, Snc1 and Snc2, localize to secretory vesicles and are required for normal bulk secretion in Saccharomyces cerevisiae. Here we have used Snc deletion mutants and chimeric Snc-VAMP proteins to demonstrate that these v-SNAREs can be dissected into regions that are either indispensable or dispensable for exocytic function in vivo.
Soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) 1 receptors (SNAREs) comprise several families of evolutionarily conserved, membrane-localized receptors for components of the vesicle docking and fusion machinery in eukaryotes. These receptors are thought to participate in the fusion of carrier vesicles with their target membranes by facilitating both vesicle docking and bilayer interaction (1) . SNAREs are found on both the vesicular compartment (vSNAREs), as well as on the acceptor or target compartment (t-SNAREs), and at all levels of the secretory pathway.
We have identified two proteins that act as v-SNAREs on carrier vesicles of the late secretory pathway in yeast. These proteins, Snc1 (2) and Snc2 (3) , are homologs of neuronal proteins known as synaptobrevins or VAMPs (4, 5) and a nonneuronal, constitutively expressed form known as cellubrevin (6) . Synaptobrevin/VAMPs were first identified as components of synaptic vesicles (4, 5) and were also isolated as elements that participate in the binding of SNAP proteins in vitro (7, 8) .
Genetic studies demonstrate that Snc proteins are required for vesicle docking and fusion (3, 9) . Yeast cells lacking Snc protein expression accumulate secretory vesicles and fail to secrete normally. In addition, these cells show conditionallethal phenotypes that result from the blockage of vesicle fusion. Like their neuronal counterparts, Snc proteins are thought to interact physically with t-SNAREs from the plasma membrane to form a putative SNARE complex (9, 10) . Specifically, these comprise members of the Sec9/SNAP-25 (10, 11) and Sso/syntaxin (12) (13) (14) families. Snc proteins co-precipitate with the Sec9 (9, 10) and Sso proteins (10) from yeast detergent extracts, and genetic studies suggest that Sec9 function in exocytosis may be Snc-dependent (9) . Recently, we have determined that Snc proteins are modified by the palmitoylation of unique cysteine residues located proximal to their transmembrane domains (15) . Palmitoylation is required to yield the mature form of the protein but is not necessary for exocytic function.
Synaptobrevin/VAMP and Snc proteins are conserved type II membrane proteins. They consist of a variable region of ϳ30 residues at the amino terminus, followed by a conserved region (ϳ60 residues) bearing two predicted amphipathic ␣-helices separated by a nonhelical spacer, and a single membranespanning domain at the carboxyl terminus (16, 17) . The variable and conserved regions are cytosolic, whereas the 3-4 residues adjacent to the membrane-spanning domain are likely to be intravesicular. The first helix of the conserved region of synaptobrevin/VAMP (known as helix 1 and designated here as "H1") contains a signal for the targeting to synaptic-like microvesicles in PC12 cells (18) . The second helix of synaptobrevin/VAMP (known as helix 2 and designated here as "H2") is thought to participate, along with H1, in the interaction with cognate t-SNAREs from the presynaptic membrane (e.g. SNAP-25 and syntaxins A and B), based upon in vitro studies (18 -20) . These v-and t-SNARE interactions are thought to result from the formation of coiled-coil structures involving the amphipathic ␣-helices of the individual SNARE partners.
To address whether specific regions within the synaptobrevin/VAMPs confer the SNARE-SNARE interactions that lead to exocytosis, we have used the yeast system to perform a structure/function analysis of the Snc v-SNAREs. By using genetic and biochemical assays, we demonstrate that the ability of Snc proteins to confer exocytic function in vivo corresponds to their ability to interact genetically with components of the putative fusion complex (Sec17, Sec9, and Sso2). We also demonstrate that the H1 and H2 segments together mediate the exocytic functions of these v-SNAREs. In addition, there is a distinct requirement for the membrane-spanning domain but no requirement for the intravesicular and variable regions. The latter suggests that this region is unlikely to act in a fusogenic capacity, as proposed for the amino terminus of the hemagglutinin antigen (HA), a viral fusion protein bearing similar structural motifs (reviewed in Ref. 21 ).
EXPERIMENTAL PROCEDURES
Media, DNA, and Genetic Manipulations-DNA restriction endonucleases, Taq polymerase, and T4 DNA ligase were used as recommended by the suppliers. Molecular cloning techniques were performed as described by Sambrook et al. (22) . DNA sequencing was performed using the dideoxynucleotide chain termination method (23) . The polymerase chain reaction (PCR) and subcloning of PCR products were carried out as described previously (24) .
Yeast were grown in standard growth media containing either 2% glucose or 4% galactose as a carbon source. Synthetic complete and drop-out media were prepared similar to that described by Rose et al. (25) . Standard methods were used for the introduction of DNA into yeast, the preparation of genomic DNA, and for tetrad dissection (25) .
Phenotypic and Biochemical Assays-Assays for cell growth on amino acid-rich medium (YPD) and temperature-sensitive growth on synthetic medium at 37°C were performed as described (24) . The secretion of invertase was measured according to the method of Goldstein and Lampen (26) .
Construction of SNC Deletion Mutants and SNC1-VAMP2 Chimeric Genes-We created two types of SNC1 deletion mutants, 5Ј-and 3Ј-truncation mutants. These mutants were created using PCR and oligonucleotides designed to amplify specific regions of SNC1. We also created chimeric SNC1-VAMP2 genes by PCR or site-directed mutagenesis. The oligonucleotides used in these reactions as well as the plasmid constructs generated are listed in Tables I and II, respectively. All mutant SNC1 and VAMP genes contain the proper initiation and termination signals, where appropriate. All mutant SNC1 and VAMP genes were subcloned into the SalI and SacI sites of either the pAD54 or pAD4⌬ high copy expression vectors, which express these genes under the control of the ADH1 promoter. For gene expression in single copy, BamHI fragments containing the ADH1 promoter and mutant SNC1 or VAMP gene were subcloned into the BamHI site of the pRS315 centromeric vector. Gene constructs were verified by restriction endonuclease analysis, and protein expression in snc cells was verified by Western analysis.
For the PCR amplification of SNC1, or regions of SNC1, either genomic SNC1 (vector YEpSNC1 (2)) or SNC1 cDNA (vector pALT-SNC1 (15)) was used as template. Vector pRc/CMV-VAMP2 was used to amplify VAMP2 cDNA in the PCR reaction. With the exception of SNC1 vamp69-84 , all chimeric SNC1-VAMP2 genes were created by splice overlap extension (27) . Briefly, the reactions were performed in two steps; in the first set of reactions hybrid fragments were generated with specific oligonucleotides for each chimera, using standard PCR conditions (94°C for 1.5 min, 42-50°C for 1.5 min, and 72°C for 2.0 min). Following gel purification, the fragments were placed in a second PCR reaction, lacking oligonucleotides, and overlap-extended to generate the full-length chimeras. Chimeric genes were sequenced to verify the correct placement of the appropriate yeast or mammalian sequences and removal of native sequences.
Plasmids-Vectors included the following: YEp13M4, a 2-m plasmid bearing the LEU2 marker; pAD4⌬, a similar plasmid that bears the ADH1 constitutive promoter (28); pAD54, a plasmid identical to pAD4⌬ but contains an oligonucleotide encoding a peptide derived from HA; and pAD6, a similar plasmid that bears an oligonucleotide encoding a peptide derived from the Myc protein. Directional subcloning into pAD54 or pAD6 allows for the in-frame fusion between the sequence encoding the epitope and the coding region of the subcloned gene of interest. Centromeric vectors included pRS315, which bears a LEU2 marker, and pSE358, which bears a TRP1 marker.
Previously described plasmids included the following: pADH-SNC1, which contains genomic SNC1 cloned into pAD4⌬ (2); pADH-HASNC1, which contains genomic SNC1 cloned into pAD54; and pTGAL-SNC1 (pGAL-TSNC1), a plasmid that expresses SNC1 under the control of the GAL10 promoter in pSE358 (3) . Plasmid pRc/CMV-VAMP2 was created by R. Trimble and was provided by R. Scheller.
Plasmid p2HL (9) 
5Ј-AACGTATTCGTCGACCATGTCGTC-3Ј
H603 (Mata ade2 can1 leu2 trp1 ura3 sso1::HIS3 sso2-1), was generously provided by Dr. Hans Ronne. Strain JG9-17 (Mata ade8 snc1::URA3 snc2::LEU2 sec17-1 pTGAL-SNC1), which contains the sec17-1 temperature-sensitive allele, was created by crossing JG4 with sec17-1 cells and dissecting tetrads from the resultant crosses to obtain strain JG4-17 (Mata ade8 leu2 trp1 snc1::URA3 sec17-1). Next, JG4-17 cells were transformed sequentially with plasmid pTGAL-SNC1 and a linear DNA fragment containing the LEU2 disruption of SNC2 to yield JG9-17 cells. Disruptions were verified by Southern blot analysis. The LEU2 disruption of SNC2, in JG9-17 was itself disrupted by a fragment containing an ADE8 marker to yield strain JG9-17A (Mat ␣ snc1::URA3 snc2::leu2::ADE8 sec17-1 pTGAL-SNC1).
Immunoblot Analysis-Protein expression in log phase-grown yeast cells was verified by immunoblot analysis using chemiluminescence, as described (9) . Anti-HA antibody (12CA5) from mouse ascites fluid was used as the primary antibody.
Thin-section Microscopy and Immunogold Labeling-Thin sectioning of yeast cells and immunogold labeling was performed as described by Zelicof et al. (30) . Affinity purified 12CA5 antibody was used to label the thin sections.
RESULTS

Mutant Analysis of Snc v-SNAREs: Deletion Mutagenesis of Snc1-We have shown that yeast bearing null alleles of SNC1
and SNC2 display conditional-lethal phenotypes that result from a blockage in cellular secretion (3) . Specific defects, such as temperature-sensitive (ts) growth at 37°C and an inability to grow on amino acid-rich medium (YPD) (3), are secondary events that occur, most probably as a consequence of the accumulation of secretory vesicles and the resulting block in exocytosis.
To determine which domains of these v-SNAREs mediate SNARE complex formation and exocytosis, we created and tested a variety of epitope-tagged Snc deletion mutants and chimeric Snc-VAMP proteins in snc null yeast. We tested for the ability of these mutant proteins to confer temperature resistance, growth on YPD, normal cellular morphology, and the secretion of invertase in the absence of native Snc protein.
In addition, we tested the effects of both single and multi-copy gene expression of the mutant proteins upon these processes.
The mutant proteins expressed and their ability to suppress the snc null phenotype are represented diagrammatically in Figs. 1 and 2. The results for the secretion of invertase are given in Table III . Protein expression of all mutants was examined by Western blotting; levels of mutant proteins expressed under the control of the ADH1 promoter from single copy plasmids were assessed to be typically ϳ1.5-2-fold over the native level of expression of individual Snc proteins in wild-type yeast, whereas those of mutant proteins expressed from multi-copy plasmids were approximately 10-fold higher in most cases (3, 15 , and data not shown).
Expression of the individual deletion mutant proteins in snc yeast demonstrates that deletion of the H1 segment (residues 31-50) or the H2 segment (residues 57-81) results in proteins that are incapable of suppressing snc null defects. Such cells remain ts, are unable to grow on amino acid-rich medium, are morphologically abnormal (summarized in Fig. 1 ), and fail to synthesize (to wild-type levels) and secrete invertase, an enzymatic marker for cellular secretion (Table III) . The decreased levels of invertase synthesis in the snc strain (relative to wildtype cells) correspond to an overall decrease in the rate of protein synthesis but do not reflect any loss in viability of the strain under experimental conditions. 2 Since the snc phenotype occurs as a direct result of the blockage in secretion, we conclude that these mutant Snc proteins do not confer exocytic function. Similarly, removal of the variable and H1 regions (residues 2-52) of Snc1 together or deletion of the transmembrane domain (residues 90 -117) also results in nonfunctional proteins ( Fig. 1 and data not shown) .
In contrast, we found that deletions in the variable region appear to be well tolerated. For example, deletion of residues 2-17 or 2-27, which remove most or all of this region, result in mutant v-SNAREs that fully suppress the growth defects of the snc null strain, when expressed either from single copy or multi-copy expression vectors (Fig. 1 , Table III , and data not shown). Similarly, deletion of the putative intravesicular region (residues 115-117) also had no effect upon the ability of the mutant protein to suppress the snc phenotype ( Fig. 1 and data not shown). Thus, each of the predicted ␣-helical segments (H1 and H2), as well as the membrane-spanning domain, appear to be indispensable for v-SNARE function in vivo. In contrast, neither the variable nor intravesicular regions appear to play a significant role in mediating the exocytic functions of Snc proteins.
Mutant Analyses of Snc Proteins: Use of Chimeric Snc1-VAMP2 Proteins-To demonstrate whether heterologous expression of the mammalian proteins is capable of restoring exocytosis in Snc-deficient yeast, we have expressed rat VAMP1 and VAMP2 in snc cells and determined whether they can confer Snc protein functions ( Fig. 2 and Table III) . Overexpression of either native or epitope-tagged VAMP1 or VAMP2 was unable to confer the ability of snc cells to grow at 37°C or on YPD, to restore normal morphology, or to secrete invertase. It would appear that although these proteins are homologous (ϳ35% identical), they have diverged sufficiently so that heterologous expression of the mammalian forms is unable to suppress the snc phenotype.
We next tested whether various chimeric Snc1-VAMP2 proteins, which contain the conserved ␣-helical segments, might confer function. A chimera (VAMP2 snc91-117 ) that contains the H1 and H2 segments of VAMP2, coupled to the transmembrane domain of Snc1, was found to be nonfunctional, as were chimeras bearing both the variable and H1 regions of Snc1, along with the H2-containing region of VAMP2 (Snc1 vamp54-93 and Snc1 vamp49-116 ) (Fig. 2) . These results suggested that the region encompassing the H2 helix of VAMP (including residues flanking the H2 segment as well as the nonhelical spacer) is unable to substitute for the same H2-containing region of Snc1. Together, these results suggested that neither the H1 nor H2 segments of Snc1 are sufficient by themselves to confer function in the absence of a corresponding native H1 or H2 segment.
Surprisingly, a chimera that contained residues 69 -84 of VAMP2 (Snc1 vamp69-84 ) was found to impart Snc functions to snc cells (Fig. 2 and Table III ). This sequence contains much of the VAMP H2 region (residues 60 -88) but lacks the areas flanking H2, including the region that connects the ␣-helical segments. This implies that a portion of the rat H2 helix is able to substitute for the same region of the yeast H2 helix.
Genetic Interactions between Snc Proteins and the ␣-SNAP Homolog, Sec17-To test whether the mutant proteins interact with components of the putative fusion complex in yeast, we examined their ability to suppress the synthetic lethality seen between snc null mutations and a ts mutation in sec17. A synthetic lethal condition was described previously between a mutation in SEC9, the yeast SNAP-25 homolog, and disruptions in the SNC genes (9) . In contrast, this condition is not seen with earlier-acting components of the secretory pathway; for example, no synthetic lethality occurs in tandem with mutations in sec6 or with deletions in pep12 (Ref. 9 and data not shown). We predict then that only components of the putative fusion complex will display such a relationship.
A candidate for this type of interaction is Sec17, the yeast homolog of ␣-SNAP (31). ␣-SNAP is a component of the 20 S 
FIG. 2. Chimeric mutant analysis of yeast Snc1 protein.
Tagged Snc1-VAMP2 chimeras were assayed for their ability to confer normal cellular growth, morphology, and invertase secretion to snc cells (JG8 T15:85). The results of these separate assays are summarized. Assessment of the activities of these mutant constructs is as defined in Fig. 1 . A diagram of the general domain structure of the Snc-synaptobrevin family of proteins is given below the representations of the various chimeras. The shaded region in these mutants corresponds to the Snc1 transmembrane domain. The hatched region in these mutants corresponds to the VAMP2 transmembrane domain. Numbers listed above the diagrams correspond to the appropriate amino acid residues contributed from either Snc1 or VAMP2. Numbers in the name of the protein expressed indicate those residues replaced by either VAMP2 or Snc1 sequences. fusion complex and associates directly with the complexed vand t-SNAREs: SNAP-25, syntaxin, and VAMP (reviewed in Ref. 1). To demonstrate whether this relationship is paralleled in yeast, we created snc1 snc2 sec17-1 triple mutants (JG9-17A cells) and tested them for viability. As determined previously for snc sec9-4 cells, snc sec17-1 cells were inviable in the absence of Snc protein (Table IV and data not shown). Such cells were viable at 25 and 30°C only when SNC1 gene expression was induced from a galactose-inducible promoter on galactosecontaining medium but not on glucose-containing medium at any temperature. This demonstrates a condition of synthetic lethality, and thus, we tested whether expression of the mutant Snc proteins could suppress it.
snc sec17-1 cells expressing either Snc deletion mutants or Snc-VAMP chimeras were tested for viability on medium containing glucose at 25 or 30°C. The structural requirements for suppressing the condition of synthetic lethality were found to be identical to those described above for conferring exocytosis (results are summarized in Table IV ). Deletion of intravesicular region did not alter the ability of mutant Snc protein to suppress the lethality; however, deletion of the H1 or H2 effectively blocked suppression. Similarly, Snc-VAMP chimeras that are ineffective in restoring normal growth to snc cells were found to be equally ineffective in suppressing the synthetic lethality. Thus, the ability of Snc deletion mutants or chimeras to confer normal growth appears to correlate with their ability to interact genetically with the SEC17 gene product.
Genetic Interactions between Snc Proteins and Their t-SNARE Partners-
We previously demonstrated that the overexpression of Snc proteins suppresses defects in the temperature-sensitive sec9-4 allele (9). Thus, overexpression of a v-SNARE protein can compensate for defects in its cognate t-SNARE, perhaps by stabilizing the mutant protein.
Here, we have examined whether the Snc mutants can also suppress the ts defects in their t-SNARE partners, Sec9 (a SNAP-25 homolog) and Sso2 (a syntaxin B homolog), in their respective mutant backgrounds (sec9-4 and sso2-1). As shown previously, overexpression of Snc1 was capable of suppressing defects in both Sec9 (9) and Sso2. 3 Likewise, overexpression of those mutant Snc proteins capable of suppressing the growth defects of snc cells (Figs. 1 and 2 , Table III ) and conferring viability to the snc sec17-1 cells were also able to confer full or, at least, partial suppression to sec9-4 cells at 35.5°C and sso2-1 cells at 37°C (see Table IV ). In contrast, the Snc1 ⌬2-27 mutant, which lacks the variable region, was found to be unable to confer suppression, unlike Snc1 or Snc1 ⌬2-17 . Proteins unable to suppress in the prior experiments also had no function in these assays. Interestingly, we found that overexpression of the Snc1 ⌬31-50 and Snc ⌬57-81 proteins retarded the growth of both sec9 and sso2 cells, under normally permissive conditions (Յ30°C) (data not shown). Thus, Snc proteins and Snc mutants that confer exocytic function also suppress ts defects in their t-SNARE partners. Correspondingly, those mutants that did not confer exocytic function also did not interact genetically with the mutant t-SNAREs.
Localization of Snc-VAMP Chimeric Proteins in Yeast-Since most chimeric Snc-VAMP proteins were nonfunctional, we sought to determine whether they can sort to secretory vesicles and reach the plasma membrane. This could serve to differentiate between those proteins that are nonfunctional due to mislocalization (i.e. trafficked to the vacuole) but might otherwise be competent for conferring vesicle docking and fusion. We 3 H. Ronne, personal communication. (JG9 -17A) was transformed with plasmids expressing the Snc1 deletion and Snc1-VAMP2 chimeric mutants from both single (CEN) and multi-copy vectors (2 m). Transformants were maintained on selective minimal medium containing galactose in order to induce SNC1 gene expression and suppress the synthetic lethality seen between the mutations. Patched transformants were then replicaplated onto the experimental conditions to test for their ability to grow on selective minimal medium at 25, 30, and 37°C, selective minimal medium containing galactose at 37°C, and amino acid-rich medium 30 C (YPD). Yeast stains bearing ts defects in t-SNAREs from the plasma membrane: sec9 -4 (NY782) and sso2-1 (H603) were transformed with plasmids expressing the Snc1 deletion and Snc1-VAMP2 chimeric mutants in multi-copy. Patched transformants grown at 25°C were replica-plated onto the experiment conditions to test for their ability to grow on selective medium at 30, 35.5, and 37°C. A ϩϩ symbol indicates that the constitutively expressed protein fully suppresses the synthetic lethality seen between snc and sec mutations. A ϩ symbol indicates partial suppression, and a Ϫ symbol complete inviability. ND indicates not determined.
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previously demonstrated the localization of Snc proteins to post-Golgi secretory vesicles using both thin-section microscopy and subcellular fractionation techniques (3). Here, we have used thin-section microscopy, together with immunogold labeling, to detect and localize HA-tagged proteins in the lateacting sec6 mutant. sec6 cells accumulate secretory vesicles when they are shifted to nonpermissive temperatures (37°C) (32) , and under these conditions Snc proteins localize to the vesicle population (3, 15) . In contrast, under conditions permissive for growth, no vesicle accumulation is seen, and Snc proteins are found primarily on the plasma membrane. We examined the localization of tagged Snc-VAMP proteins overexpressed in sec6-4 cells that were shifted to nonpermissive temperatures for 1 h (Fig. 3) . As a control, Snc1 was found to localize to the vesicle population that accumulates under these conditions but was not detected in significant quantity on the plasma membrane (quantified on the basis of gold particle distribution to vesicles vis à vis the plasma membrane; data not shown). In a similar fashion, both Snc1 vamp49-116 and Snc1 vamp54-93 were also found to localize to secretory vesicles, indicating that substitution of the H2 and transmembrane regions of Snc1 by the corresponding VAMP2 sequence(s) had no deleterious effect upon protein localization. In contrast, VAMP2, along with VAMP2 snc91-117 , were found to localize primarily to the plasma membrane. Thus, both functional and dysfunctional Snc proteins were found to reach the plasma membrane.
It should be noted that similar results were obtained with sec6 cells expressing the tagged proteins from single copy plasmids, although the degree of labeling was substantially less (data not shown). Also, when localization studies were performed on sec6 cells maintained at permissive temperatures, the distribution of gold particles was similar for all mutant proteins examined and was found to be almost exclusively associated with the plasma membrane, as shown previously for Snc1 (3) and Snc1
Ser-95 (15) (data not shown).
DISCUSSION
Yeast Snc proteins are archetypal v-SNAREs of the late secretory pathway. These proteins share structural homology with members of the synaptobrevin/VAMP/cellubrevin family and engage in similar exocytic functions. Like their brethren, Snc proteins localize to secretory vesicles (3), interact with t-SNAREs from the plasma membrane (9, 10, and this study), FIG. 3 . Sorting of Snc-VAMP chimeric proteins to secretory vesicles and the plasma membrane in sec6 cells. The localization of HA-tagged Snc1, VAMP2, and various Snc1-VAMP2 chimeric mutants in temperature-shifted sec6 cells was monitored by thin-section microscopy and immunogold labeling. sec6 cells expressing the appropriate constructs were grown at 30°C to log phase prior to temperature shifting to 37°C for 1 h. Cells were then harvested and processed for thin-section microscopy and immunogold labeling, using anti-HA antibody ( and are likely to undergo a dynamic cycle of transport to, and retrieval from, the plasma membrane.
Here we have demonstrated that the conserved amphipathic ␣-helical region (residues 32-85) is essential for conferring the exocytic functions of these v-SNAREs. Deletions or gross substitutions in either of the predicted H1 or H2 segments result in a complete loss of function of the proteins, although they appear to reach secretory vesicles and the plasma membrane. Thus, as was predicted by experiments performed in vitro with mammalian v-and t-SNAREs (18 -20, and 33) , it would seem likely that both helices are required for SNARE complexing in vivo. Although we cannot say whether the individual helices prefer specific t-SNARE partners, it appears that both helices can interact either with Sec9 or Sso2. This is based upon the result that Snc proteins lacking in either H1 or H2 are unable to suppress ts defects in either Sec9 or Sso2 and inhibit the growth of sec9 and sso2 cells at permissive temperatures. These proteins, Snc1
⌬31-50 and Snc1
⌬57-81
, appear to exert a dominant negative effect when overexpressed. Thus, it is possible that they compete with the native proteins in undergoing SNARE partnering but are unable to confer secretory functions. Interestingly, the Snc1 ⌬2-27 mutant was unable to confer suppression of the ts defects in either Sec9 or Sso2, unlike Snc1 or Snc1 ⌬2-17 , suggesting that a portion of the variable domain aids in the rescue of the mutant t-SNAREs.
Work by Hayashi et al. (19) demonstrated that the domains required for SNARE complex formation in vitro correlate well with the regions predicted to form ␣-helices. Specifically, synaptobrevin binding to the carboxyl-terminal third of syntaxin or SNAP-25 was shown to involve the entire conserved domain (residues 27-96) (19) . Earlier studies also showed binary interactions between synaptobrevin/VAMP and syntaxin (33) and SNAP-25 (20) . Deletions of both the variable region as well as the transmembrane domain of synaptobrevin were found to have no deleterious effect upon complex formation and, in contrast, were found to enhance the interaction (19) . Here, using in vivo studies with mutant Snc proteins, we have shown that the structural requirements that lead to secretion are quite similar to those proposed for SNARE complex formation in vitro. In our study, however, the transmembrane domain of the protein is required for function, probably due to its membrane anchoring capacity. This is likely to be essential for the localization of Snc proteins to secretory vesicles, although it may be unnecessary for SNARE complex formation per se.
Importantly, the results obtained in our in vivo study have been collaborated by a recent work in which the regions of VAMP required for conferring Ca 2ϩ -mediated exocytosis from permeabilized insulin-secreting HIT-T15 cells were examined (34) . By using tetanus toxin-resistant mutants of VAMP, the authors demonstrate that deletions in either of the amphipathic ␣-helices inhibited the ability of these mutants to restore exocytosis in tetanus toxin-treated cells. In addition, deletion of the variable region (residues 2-31) had no effect upon VAMP2 function, as shown here for Snc1. Moreover, the ability of these mutants to bind to either syntaxin Ia or SNAP-25 in vitro paralleled their ability to confer exocytic functions. Thus, the results obtained in our mutational analysis of the yeast synaptobrevin/VAMP homologs are identical to those obtained for VAMP using a permeabilized cell system.
It has been suggested that the amino terminus of the synaptobrevin/VAMP proteins might act in a fusogenic capacity (35) to confer bilayer fusion in the manner described for the fusion peptides of the influenza hemagglutinin antigen. This study suggests that removal of the amino-terminal variable region of a yeast v-SNARE has no deleterious effect upon its ability to confer exocytosis in snc cells. Thus, the likelihood that this region would act in an essential fusogenic capacity would seem slight. This is supported by the previous study (34) , yet neither work can rule out the possibility that the H1 segment alone could act in the capacity of a fusion peptide, if such a mechanism were indeed operant.
Although no well defined role for the variable region has been described, other studies suggest that it may be involved in neuronal transmission. For example, peptides corresponding to the variable region of VAMP2 (but not VAMP1) inhibit acetylcholine release from Aplysia neurons (36) and the interaction between VAMP and synaptophysin in vitro (37) . Therefore, the role of the variable region could have additional functions in higher eukaryotes and may well be cell-and isoform-specific. As no synaptophysin/synaptoporin homologs have been identified in yeast thus far, we are unable to determine whether this interaction (38, 39) is involved in constitutive exocytosis in lower eukaryotes.
Another study has demonstrated the requirements for the sorting of VAMP proteins to synaptic vesicles (18) . There the authors show that the synaptic vesicle sorting signal for both VAMP and cellubrevin is contained within the H1 segment. Removal of residues within H1 was shown to block targeting to synaptic vesicles, whereas alanine-scanning mutagenesis revealed that certain hydrophobic residues that participate in the heptad repeat of the H1 helix are important for sorting (18) . These mutations are likely to decrease the overall hydrophobicity of the helix and to lessen its ability to form a coiled-coil structure.
In our study, we have found that both VAMP2 and VAMP2 snc90-117 are likely to target to secretory vesicles and reach the plasma membrane when expressed in yeast. Yet these proteins are deficient in conferring exocytosis, as well as in localizing in quantity to secretory vesicles, during vesiculation in sec6 cells. In contrast, Snc1 and several Snc-VAMP chimeras (e.g. Snc1 vamp49-116 and Snc1 vamp54-93 ) associated primarily with the vesicles under the same conditions. Therefore, it would seem likely (although not exclusively) that certain sequences in Snc1 confer protein retrieval from the plasma membrane. In our labeling experiment, we cannot differentiate between proteins contributed from the biosynthetic pool and those recycled from the cell surface. Yet, because those proteins that bore the Snc1 H1 segment underwent a significant relocalization to the vesicle population (upon vesiculation), we are inclined to believe that the H1 of the yeast homologs, like that of synaptobrevin/VAMP, may play a role in protein sorting to vesicles. Correspondingly, those chimeras which possess the VAMP2 H1 segment associated primarily with the plasma membrane and not with vesicles. Perhaps, then, the cellular machinery required for Snc retrieval is unable to recognize efficiently the H1 domain of the mammalian isoforms. More work will be required to fully address these issues.
Overall, there is a significant degree of structural as well as functional homology between the Snc and synaptobrevin/ VAMP proteins, despite the fact that they confer different exocytic programs in vastly diverged systems. Some differences remain to be resolved, but the beauty of these v-SNAREs lies in their overwhelmingly simple structure and conserved set of interactions and functions. Solving the tertiary and quaternary structures of these proteins will ultimately shed light upon how they act in mediating SNARE complex formation and exocytosis.
